Class III Milk (DC)

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Dakota Gold a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Dakota Gold..

Dakota Gold (AMEX:DC) Azioni, Catena delle Opzioni

Dakota Gold

Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.

Dakota Gold Corp

Dakota Gold Corp. Warrants, each warrant exercisable for one Common Share at an exercise price of $2.08

DANIELS CORP ADVISOR by Daniels Corporate Advisory Co Inc

Daniels Corporate Advisory Co Inc

Unity Wealth Partners Dynamic Capital Appreciation & Options ETF

Docebo Inc

Dacian Gold Ltd

DCC PLC

BNY Mellon Alcentra Global Credit Income 2024 Target Term Fu Com

Tritium DCFC Ltd

DocGo Inc

DAINICHISEIKA COLOUR CHEM by DAINICHISEIKA COLOUR & CHEMICALS MFG CO LTD.

Dainichiseika Color & Chemicals Mfg Co Ltd

DACHAN FOOD ASIA LIMITED by DACHAN FOOD ASIA LIMITED

DIGITAL CHINA HOLDINGS by Digital China Holdings Ltd.

Digital China Holdings Ltd

DIGITAL CHINA HLDGS ADR by Digital China Holdings Ltd.

SHANGHAI HUAYI GRP CRP B by Shanghai Huayi Group Corporation Limited

Shanghai Huayi Group Corp Ltd

Dechra Pharmaceuticals PLC

Discovery Harbour Resources Corp

DISCOVERY HARBR RES CORP by DISCOVERY HARBOUR RES CORP.

Donaldson Co Inc

DISCOVERY ENGY METALS CRP by Discovery Energy Metals Corp.

Discovery Energy Metals Corp

DATA CALL TECHS INC by Data Call Technologies, Inc.

Data Call Technologies Inc

DATA COMMUN MGMT CORP by Data Communications Management Corp.

DATA Communications Management Corp

DCM Holdings Co Ltd

DoubleLine ETF Trust DoubleLine Commodity Strategy ETF

Dentacoin

Canadian Palladium Resources Inc

QUEST CRITICAL METALS INC by QUEST CRITICAL METALS INC.

Quest Critical Metals Inc

DAI-ICHI LIFE HLDGS INC by Dai-ichi Life Holdings, Inc.

Dai-ichi Life Holdings Inc

Ducommun Inc

DICKSON CONCEPTS INTL HK by Dickson Concepts International Ltd.

Dickson Concepts (International) Ltd

Dime Community Bancshares, Inc. - Common Stock

Dime Community Bancshares Inc

Dime Community Bancshares, Inc. - 9.000% Fixed-to-Floating Rate Subordinated Notes due 2034

Dime Community Bancshares, Inc. - Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A

Dimensional ETF Trust Dimensional US Core Equity 1 ETF

DECIPHERA PHARMACEUTICALS INC COM

DANCANN PHARMA A/S NEW by DanCann Pharma A/S

DanCann Pharma AS

Decred

DoubleLine ETF Trust DoubleLine Commercial Real Estate ETF

DIRECT COMM SOLUTIONS INC by Direct Communication Solutions, Inc.

Direct Communication Solutions Inc

Direct Communication Solutions Inc Ordinary Shares

DCT Industrial Trust Inc Com (New)

Delcath Systems Inc

REGENERA INSIGHTS INC by REGENERA INSIGHTS INC.

Regenera Insights Inc

DISCOVERY HLDGS LTD ORD by Discovery Holdings Ltd.

Discovery Ltd

DISCOVERY HLDGS UNSP/ADR by Discovery Holdings Ltd.

Saint Herblain (France), April 14, 2025 – <a href="https://www.globenewswire.com/Tracker?data=ePwnzLsA9q6uMhM8Oi7Np1HNRMVaOsYBynQ5-kDFraAO2xMMVLDlLeF4eGtulTn_CNkznL0Vw33HgPIPH5I6CgNaoDyL0PLqXjFV9EEuO4E=">Valneva SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>, PARIS:<a class="ticker" href="https://www.benzinga.com/stock/VLA#PARIS">VLA</a>), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ&#xAE; for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The ANVISA decision marks the world's first approval of a chikungunya vaccine in an endemic country. Part of Valneva's endemic country strategy, this endeavor is supported by the Coalition for Epidemic Preparedness Innovations (CEPI)1, with co-funding from the European Union (EU), and Instituto Butantan2 to support broader access to a chikungunya vaccine in low-and-middle-income countries (LMICs).
IXCHIQ&#xAE; is the world's first licensed chikungunya vaccine available to address this significant unmet medical need. In addition to Brazil, IXCHIQ&#xAE; is approved for the prevention of disease caused by the chikungunya virus in people aged 12 years and older in the EU, and in people aged 18 years and older in the United States (U.S.)3, Canada4 and the United Kingdom (U.K.)5. Label extension applications to adolescents were submitted in the U.S., Canada and the U.K.
This important approval primarily enables initiation of large-scale clinical trials of IXCHIQ&#xAE; in Brazil, including the committed Phase 4 clinical trials supporting IXCHIQ&#xAE;'s approval by the U.S. Food and Drug Administration (FDA) and the European Commission to generate additional data on vaccine effectiveness. CEPI is providing funding support to these trials.
ANVISA continues to review VLA1555, the chikungunya vaccine candidate which, if approved, will be locally manufactured and distributed by Instituto Butantan pursuant to its collaboration with Valneva. Potential approval is anticipated in mid-2025. Instituto Butantan is committed to providing a locally manufactured vaccine at an affordable price in Latin America and selected LMICs.
Valneva and Instituto Butantan are working together to ensure fast access to its chikungunya vaccines for the Brazilian market and other countries in the region as quickly as possible. The Americas saw nearly 300,000 chikungunya cases and 300 deaths attributed to the virus between January and July 2023, totaling more than 720,000 cases since 20206. Brazil has reported the highest number of cases, with over 1 million total between January 2019 and July 2024.
Supported by CEPI and the EU's Horizon program, Valneva remains focused on expanding the vaccine's access in LMICs. In December 2024, Valneva announced a new partnership with the Serum Institute of India (SII), the world's largest manufacturer of vaccines by number of doses, enabling supply of the vaccine in Asia7.
Additionally, as part of the CEPI and EU support, Valneva is conducting a Phase 2 trial in children aged 1 to 11 years in the Dominican Republic and Honduras, for which it reported positive results in January 2025. The trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the fourth quarter of 2025, with the objective to extend the product label to this age group. Valneva is also expected to evaluate the vaccine in pregnant women in countries affected by chikungunya outbreaks, like Brazil.

News

PARIS:VLA

VALN

Valneva Gets First Marketing Authorization From ANVISA For Single-dose Vaccine IXCHIQ In Chikungunya Endemic Country

Macro Economic Events

Global

Economics

CPRI

LVMHF

Watching Capri, Tapestry; LVMH Reportedly Says The U.S. Saw A Slight Decline, Despite A Good Performance In Fashion & Leather Goods And In Watches & Jewelry; In A Disrupted Geopolitical And Economic Environment, LVMH Remains Both Vigilant And Confident At The Start Of The Year

Investing might look easy for some, but that isn&#8217;t always the case. For a young <a href="https://www.benzinga.com/personal-finance/25/04/44658629/23-year-old-investor-with-75k-portfolio-1-8k-dividend-income-reveals-top-assets-asks-what-i-should-look-at-or-add-to-reddit-debates">investor</a> with a long time horizon, the decision to hold onto individual stocks or shift into broad-market <a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order">ETFs</a> can be pivotal.
While concentrated bets on high-growth companies can yield amazing returns, they also come with heightened volatility and sector risk. On the other hand, index funds provide stability and market-matching returns but may lack the explosive upside of single-stock picks.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
The debate becomes even more pressing when an investor is sitting on unrealized losses. Should they cut their losses and reallocate, or hold firm, trusting their long-term goal will come to be? The answer often depends on risk tolerance, time horizon, and the strength of their investment motivation.
One Reddit user, a 23-year-old investment banker, has shared his concerns regarding his portfolio on the online discussion board. The poster has a $58,000 portfolio but is currently down around $4,000 on his holdings.
His portfolio is heavily concentrated in tech giants, including Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>, GOOG)), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)​, Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), alongside Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) and Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)).
The poster shared that he can save $6,000 per month from his salary, allowing consistent investments, and he&#8217;s in for the long run. He&#8217;s also acknowledged that his portfolio is tech-heavy but says he plans to dilute exposure by dollar cost averaging into VOO monthly. Although he&#8217;s down on his Magnificent 7 stocks, he is unfazed, saying it is a great discount opportunity.
&#8220;I see this as a perfect opportunity to pick up more shares of great companies at discounted prices. I'm down close to $4,000 so far from my Mag7 holdings. Do you suggest I sell at a loss and reallocate into VOO or hold on to it and ride it out?&#8221; he asked.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The comment section exploded with mixed opinions, so let&#8217;s dive into those.
<h2 class="wp-block-heading">Reallocate Mag7 Stocks Into VOO Or Hold On It And Ride It Out?</h2>
Sell Individual Stocks and Go All-In on VOO or Diversified ETFs
Many commenters argued that the investor's portfolio lacks diversification and overlaps with VOO's top holdings, making it redundant.
&#8220;Buy VOO and you'll have all of those under one position,&#8221; a comment reads.
&#8220;Terribly un-diversified. Just buy an index fund. It has all those,&#8221; another Redditor suggested.
This user recommended selling individual stocks and adding global diversification to the portfolio.
&#8220;I will suggest more ETFs. VOO is already overweight in the individual stocks you have, for the most part, so your diversity is lacking. Personally, I would sell all except for VOO and BRK.B and get some international in there,&#8221; he said.
&#8220;I would recommend diversifying with some sort of index fund or ETF. I wouldn&#8217;t sell at a loss unless you are cashing anything out and tax loss harvesting later in the year,&#8221; a comment reads.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
Hold High-Conviction Stocks but Increase VOO Allocation Over Time
Other Redditors argued that the poster&#8217;s long time horizon and high conviction justify keeping his Mag7 stocks while gradually increasing VOO exposure.
&#8220;I&#8217;d heavily caution against selling anything here. If you sell anything, immediately reinvest back into your VOO ETF or your high-conviction Mag7 stocks. The Mag7 will likely outperform the broad market for a long time. Study past &#8220;monopolies&#8221; and how long they outperformed before being disrupted (the answer is decades),&#8221; a Redditor suggested.
A commenter recommended keeping a middle-ground approach, namely keeping tech exposure but adding diversification.
&#8220;Good job, young rich homie. I&#8217;d suggest a Mag7 ETF and a diversified ETF investing in international markets, too. Diversification is the only free lunch in investing. Good luck!&#8221;
While supporting holding strong companies, this Redditor suggested making VOO the portfolio&#8217;s foundation: &#8220;A little concentration on tech. However, you own great companies and you are 23, so keep them and buy more at a discount! VOO is great as a core holding and should be the biggest slice of the pie as your portfolio grows.&#8221;
As a compromise between stock picking and diversification, a Redditor suggested a tech-heavy ETF.
&#8220;Instead of investing in the Mag7 by themselves, why not add [Invesco NASDAQ 100 ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqqm#NASDAQ">QQQM</a>)]? It has a lower expense ratio than [Invesco QQQ Trust (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>)] and it holds large tech companies, which seems to fit your philosophy at the moment. If you want growth, it's also best to diversify. How about some international exposure? [Vanguard Total International Stock ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vxus#NASDAQ">VXUS</a>)] is a great ETF, and [Vanguard Total World Stock ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vt#NYSE">VT</a>)] also has some international exposure,&#8221; he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AMZN

GOOGL

MSFT

NVDA

QQQM

VXUS

Young Banker Holding $58K Portfolio Sees Red – 'Reallocate Into VOO Or Hold On To It And Ride It Out?' – Reddit Explodes

A temporary delay in new U.S. tariffs on tech imports from China sparked <a href="https://www.benzinga.com/topic/semiconductors">a broad semiconductor rally</a>.
What Happened: The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) jumped 2.5% by 9:40 a.m. ET Monday, extending its rally to 19% from last week's lows.
Monday&#8217;s top individual gainers within the SOXX ETF included:
<ul>
<li>Entegris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) surged 6.7% to $74.37</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rose 6.1% to $20.95</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 5.8% to $73.56</li>
<li>Qorvo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) added 5.1% to $59.16</li>
<li>MKS Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) climbed 4.2% to $68.25</li>
<li>Universal Display Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>) rose 3.8% to $117.02</li>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) advanced 3.7% to $153.01</li>
</ul>
In a research note published on Monday, Bank of America analyst Vivek Arya called the one-to-two-month delay on electronics tariffs &#8220;incrementally positive.&#8221; The delay, which allows industry debate before the White House finalizes so-called &#8220;sectoral&#8221; tariffs targeting semiconductors, was enough to trigger <a href="https://www.benzinga.com/topic/chipmakers">sharp gains in chip stocks</a>.
Sentiment also improved following the U.S. Customs and Border Protection's decision Friday to exclude several electronic categories—such as smartphones and PCs—from immediate reciprocal tariffs.
"The delay is a net positive," Arya said, citing how electronics represent roughly 50% of global chip demand. 
"It allows for debate and discussion on this critical end-market,&#8221; he added. 
Arya noted that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), the world's largest semiconductor buyer, was also excluded from tariff pressure during Trump&#8217;s first term.
Arya reaffirmed a bullish stance on chipmakers with exposure to artificial intelligence and reshoring themes, including Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).
Cadence Design Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) and Synopsys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) remain his key preferences among chip-design software firms.
For semiconductor capital equipment—a group seen as direct beneficiaries of U.S. manufacturing—Arya highlighted Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) and KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>).
The analyst also noted a potential tailwind from increased domestic production efforts. Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&#8217;s $195 billion U.S. investments, Apple's $500 billion pledge and Nvidia's $200 billion U.S. expansion could all influence the shaping of final tariff rules.
"We expect over time for TSMC to front-end process most—if not all—semis required by its U.S. fabless customers within its Arizona fabs," Arya said, adding that a potential Intel-TSMC joint venture could further boost domestic chip output.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44788262/apples-margins-catch-a-break-but-road-ahead-still-looks-bumpy">Apple&#8217;s Margins Catch A Break, But Road Ahead Still Looks Bumpy</a>
Why It Matters: Despite Monday's rally, Arya maintained a cautious view on chipmakers heavily exposed to consumer-facing segments like smartphones and PCs. 
After all, President Donald Trump clarified Sunday that electronics aren&#8217;t fully exempt. They will instead be folded into a separate sector-focused tariff plan to be announced in the coming months. 
Therefore, it&#8217;s unclear how sectoral tariffs will apply to U.S. electronics assembled in China using foreign-made chips.
"Semis remain a high beta sector and exposed to volatility," Arya said. However, he expects companies tied to AI and infrastructure to remain well-positioned to deliver on earnings expectations.
One risk Arya flagged is the upcoming May 15 compliance deadline for new U.S. rules governing the export of AI chips, which could limit shipments outside a small group of 19 &#8220;Tier 1&#8221; nations.
Still, with the delay in electronics tariffs offering space for negotiation, investors appear to be betting that the worst-case trade scenarios for U.S. chipmakers could be avoided, at least for now.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44787080/goldman-sachs-cheers-china-tariff-exemptions-lifts-earnings-forecasts-for-apple-dell-hp">Goldman Sachs Cheers China Tariff Exemptions, Lifts Earnings Forecasts For Apple, Dell, HP</a></li>
</ul>
Image: Shutterstock

Asia

Equities

Large Cap

Mid Cap

Broad U.S. Equity ETFs

Tech

ETFs

AAPL

AVGO

CDNS

ENTG

INTC

KLAC

LRCX

MKSI

OLED

QRVO

SNPS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

7 Chipmaker Stocks Set To Gain As Trump Delays Tariff Blow On Key China Tech Imports: Bank Of America

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is trading 1.65% higher at $85,079.92 as of Monday morning, building on a 3% gain over the past five days and rising 3.73% over the past month. The broader crypto market appears to be stabilizing alongside equities as investors digest the White House's evolving stance on global tariffs.
U.S. stock futures rose sharply Monday, buoyed by temporary exemptions on tariffs. The relief rally extended to crypto, with <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-btc-best-bonuses-august-2024">Bitcoin moving above $85,000 as of early trading</a>.
<h2 class="wp-block-heading">Traders Target $100K as BTC Options Market Flips Bullish</h2>
Options data tracked by CoinDesk and analytics firm Amberdata shows a shift in sentiment among Bitcoin derivatives traders. After a week of defensive positioning and heavy put option demand, the market is now swinging back toward upside speculation.
The most popular open interest position on Deribit, which accounts for over 75% of global crypto options activity, is now the $100,000 Bitcoin call option—with a cumulative notional open interest approaching $1.2 billion. The resurgence signals that large traders are again positioning for a breakout as market volatility eases.
The change to positive forecasts has balanced the options skew. The 30 to 90-day skews—which measure relative demand for calls versus puts—have all climbed back into positive territory, reflecting a decisive reduction in market panic.
BTC's price recovery from last week's lows near $75,000 comes after the Trump administration backed off some of its steepest proposed tariffs, sparing key tech imports from the immediate impact of the new levy regime. While the president later refuted the exemptions, saying affected products would be moved to a "different tariff bucket," the temporary relief was enough to ignite a cross-asset bounce in risk markets.
<h2 class="wp-block-heading">Macro Tailwinds Build as Bitcoin Rides Tech-Led Rally</h2>
Stock market gains are adding to bullish sentiment. Nasdaq futures were up 1.5% Monday morning, while gold continued to hold near all-time highs above $3,200 per ounce amid renewed interest in safe-haven assets. Apple, Dell, and Nvidia shares were all up sharply in premarket trading thanks to the tariff news.
Bitcoin appears to be benefiting from both macro and crypto-native tailwinds as institutional bets on a return to six-figure valuations, easing geopolitical fears, and increasing alignment with risk-on assets like tech stocks. This week's moderation in 10-year Treasury yields—now sitting near 4.45%—has also helped alleviate pressure on digital assets.
<h2 class="wp-block-heading">What&#8217;s Next for Bitcoin?</h2>
If the $85,000 level holds, traders may begin eyeing a run toward the $88,000–$90,000 resistance range, followed by a push to retest the all-time high of $91,000 set earlier this year. However, market participants remain alert to fresh updates from the White House, particularly on semiconductor tariffs that could trigger another round of volatility.
Despite last week's dip and lingering uncertainty around global trade policy, the strength in Bitcoin options markets and rising institutional interest in the $100K level point to growing conviction that the bull cycle is still intact.
For now, Bitcoin's rebound reflects a recalibration of investor expectations as geopolitical noise settles and the crypto market regains its footing.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Reclaims Momentum As $100K Calls Resurface And Tariff Relief Lifts Market Mood

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is trading at $2.144 on Friday, down 2.99% over the last 24 hours, following a volatile stretch that saw the broader crypto market under heavy selling pressure.&nbsp;
But unlike its peers, <a href="https://www.benzinga.com/money/how-to-buy-ripple-xrp">XRP appears to be weathering the storm</a>—and possibly positioning for a stronger breakout.
While the latest pullback brought XRP off its local highs, it comes after a 20% rally over the past week, as buyers stepped in during a broader market crash that briefly sent the coin to a monthly low of $1.64. The rebound erased fears that XRP might dip below the $1 mark, a possibility now firmly off the table amid stabilizing sentiment.
Despite its modest price decline today, XRP continues to outpace wider investor trends. According to new data from CoinShares, XRP recorded $3.4 million in inflows over the past week, leading all non-Bitcoin digital assets. It came during a period where crypto investment products saw $795 million in outflows—with Bitcoin alone bleeding $751 million, and Ethereum losing $37.6 million.&nbsp;
The move suggests that investor confidence in XRP is rising, even as others scale back risk.
The contrarian inflow into XRP coincides with a major shift in the coin's long-standing legal battle. Ripple Labs and the U.S. Securities and Exchange Commission filed a joint request last week to pause their appeals in favor of pursuing a negotiated resolution.&nbsp;
The two sides have reached an agreement in principle, pending approval from the Commission. If finalized, the deal could mark the official end to a legal standoff that has defined XRP's identity in U.S. markets since 2020.
"The parties require additional time to obtain Commission approval for this agreement-in-principle," the filing said, adding that both parties will seek an indicative ruling from the court once approved. It follows the SEC's decision to withdraw its appeal of a previous ruling that XRP's programmatic sales did not constitute securities offerings—a key moment that helped redefine the regulatory outlook on digital assets.
Meanwhile, speculation continues to mount around the potential approval of an XRP-based exchange-traded fund (ETF), with some market observers pointing to BlackRock and Fidelity as potential issuers.&nbsp;
Industry voices, including pro-XRP attorney John Deaton, have suggested XRP could eventually challenge Ethereum's market dominance, given its utility in cross-border payments and real-world adoption.
Macro conditions are also relevant. The brief recovery in digital assets in the last week was aided by cooling inflation data and shifting tariff policy under Donald Trump's administration.&nbsp;
While the president <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">has walked back a blanket pause on tariffs</a>, global markets took some relief in the latest round of exemptions. XRP's resilience during the period adds weight to its growing reputation as a more insulated asset in times of uncertainty.
Looking ahead, XRP bulls will be watching the $2.20 resistance level for a possible breakout—a move that could open the door to retesting $2.38 in the near term. On the downside, $1.95 and $1.64 remain key support zones.
With legal clarity on the horizon and investor appetite holding firm even amid widespread outflows, XRP appears to be entering a new phase. While short-term volatility remains, the foundation for long-term momentum continues to strengthen.

$XRP

XRP Price Slips As Traders Brace For SEC Settlement And Market Rebound

Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) is pushing higher to start the week, extending a rebound from early April as momentum builds behind renewed ETF optimism and easing macro pressures.
Price Action
At the time of writing, Solana is trading at $132.11, up 3.76% over the last 24 hours, according to CoinMarketCap. The token is up 27% over the past week and has erased most of its recent monthly losses, <a href="https://www.benzinga.com/money/how-to-buy-solana">now down just 2.33% over the past 30 days</a>.
<h2 class="wp-block-heading">Solana ETF Bets Hit 81% Amid Market Shift</h2>
The rally follows a wave of renewed speculation around a Solana ETF, fueled by Paul Atkins' appointment as SEC chair. Atkins, a former SEC commissioner known for being crypto-friendly, has sparked hopes of regulatory tailwinds for altcoin-based exchange-traded products.
On Polymarket, traders are assigning an 81% probability that a Solana ETF will be approved by the end of 2025, up 7% since last week. That's a major increase from the 65% odds seen in early January, as shown in the platform's prediction markets.
Major firms including VanEck, Bitwise, 21Shares, Grayscale, and Canary Capital have submitted preliminary filings for Solana-based ETFs, according to Cointelegraph, and investor appetite appears to be accelerating.
<h2 class="wp-block-heading">Technical Setup Turns Bullish</h2>
According to analysts cited by Cointelegraph, SOL's recent breakout coincides with a bullish divergence in its daily RSI, indicating building upward pressure. Solana has now reclaimed its 50-day simple moving average (SMA)—currently hovering just above $132—and a sustained move higher could open the door for a retest of the $150–$153 range.
On-chain analytics firm Santiment also flagged Solana as one of the most discussed assets in crypto markets this weekend, with chatter focused on trading setups, ETF speculation, and macro catalysts.
<h2 class="wp-block-heading">Broader Market Context: Tariff Relief Supports Risk Assets</h2>
Solana's Monday rally aligns with improving sentiment across both crypto and equities following Friday's tariff reprieve from the Trump administration.&nbsp;
While initial reports suggested that smartphones and electronics were spared from sweeping 125% levies, President Trump later walked back the announcement—saying that the products are being moved into a separate "tariff bucket" for national security review.
Even so, risk assets surged on the initial announcement, with U.S. stock futures climbing and gold hitting all-time highs above $3,200 per ounce. The backdrop has provided a cushion for crypto markets broadly, with Bitcoin back above $85,000 and Ethereum hovering near $3,400.
<h2 class="wp-block-heading">The Bottom Line</h2>
Solana's rally appears to be riding multiple tailwinds: rising ETF speculation, short-seller liquidations, bullish technicals, and improving macro sentiment. If momentum holds, SOL could be well-positioned to reclaim its March highs—particularly if ETF narratives continue to gain traction in the weeks ahead.

$SOL

Solana Extends Rally As ETF Bets Climb And Market Sentiment Turns

Scotiabank analyst Tanya Jakusconek maintains Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) with a Sector Outperform and raises the price target from $79 to $87.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Wheaton Precious Metals, Raises Price Target to $87

Cruise line operator Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) announced on Sunday that it is gearing up for a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44780504/norwegian-cruise-line-holdings-announces-development-plans-for-private-island-destination-great-st" rel="noreferrer noopener">major revamp of its private Bahamian island</a>, Great Stirrup Cay. A slate of new attractions and facilities is scheduled to open by late 2025.
The cruise operator plans to enhance visitor enjoyment with a range of new features, such as a redesigned welcome center and a modernized main pool area.
These additions are expected to launch alongside a newly built pier designed to dock several vessels at once.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44774262/nikes-sneaker-buzz-and-tariff-risks-could-shape-its-future-says-analyst" rel="noreferrer noopener">Nike&#8217;s Sneaker Buzz And Tariff Risks Could Shape Its Future: Analyst</a>
&#8220;These newly announced enhancements to Great Stirrup Cay will further improve the guest experience on the island, which is already one of our top-rated destinations worldwide,&#8221; said President and CEO, Harry Sommer.
&#8220;Along with the completion of a new multi-ship pier later this year, we&#8217;re improving both access and amenities on the island. As we anticipate annual guest visits to exceed one million by 2026, we are actively evaluating additional investments in the island to support that growth and expand the amenities our guests can enjoy.&#8221;
The new features will cater to a wide range of travelers, from families to solo vacationers. Plans include a large swimming pool equipped with a swim-up bar, a splash zone for children, and cabanas for poolside lounging.
Premium amenities from the fleet are also headed to shore. The island will soon feature signature onboard experiences such as the adults-only Vibe Beach Club and Horizon Park, a leisure area focused on lawn games and open-air relaxation.
JPMorgan analyst <a target="_blank" href="https://www.benzinga.com/general/entertainment/25/03/44358050/cruise-wars-norwegian-vs-royal-caribbean-whos-ruling-the-high-seas" rel="noreferrer noopener">Matthew R. Boss recently raised his rating </a>on Norwegian Cruise Line stock to Overweight, pointing to strong consumer demand and a continued pricing advantage of cruises compared to traditional land vacations.
The company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44005238/norwegian-cruise-line-sails-past-q4-expectations-eps-soars-margins-expand-and-demand-stays-hot" rel="noreferrer noopener">fourth-quarter revenue growth&nbsp;of 6% </a>year-on-year to $2.109 billion with an occupancy percentage of 100.8%.
Norwegian Cruise Line operates three cruise brands with 33 ships and 70,050 berths, offering trips to around 700 global destinations. The company plans to expand its fleet by 12 ships by 2036, adding roughly 37,500 berths.
Price Action: NCLH shares are trading higher by 0.70% at $16.44 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44771652/versace-exit-is-capris-big-bet-on-michael-kors-revival-says-analyst" target="_blank" rel="noreferrer noopener">Versace Exit Is Capri&#8217;s Big Bet On Michael Kors Revival, Says Analyst</a></li>
</ul>
Image via Norwegian Cruise Line

General

NCLH

Norwegian Cruise Line Plans Major Upgrade To Bahamian Island Retreat

Scotiabank analyst Tanya Jakusconek maintains Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) with a Sector Perform and raises the price target from $7.25 to $8.25.

SAND

Scotiabank Maintains Sector Perform on Sandstorm Gold, Raises Price Target to $8.25

HSBC analyst Madhvendra Singh upgrades America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) from Hold to Buy and raises the price target from $15.5 to $17.5.

Upgrades

HSBC Upgrades America Movil to Buy, Raises Price Target to $17.5

Scotiabank analyst Tanya Jakusconek maintains Triple Flag Precious (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#NYSE">TFPM</a>) with a Sector Outperform and raises the price target from $21 to $23.

TFPM

Scotiabank Maintains Sector Outperform on Triple Flag Precious, Raises Price Target to $23

President Donald Trump has attacked units of media company Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and is urging the FCC to fine and punish CBS as the company works to<a href="https://www.benzinga.com/general/entertainment/24/07/39668270/paramount-analysts-size-up-merger-skydance-aims-for-earnings-not-a-breakup-redstone-says-co"> complete its merger </a>with Skydance Media.
What Happened: Trump took to his Truth Social media platform over the weekend to attack CBS newsmagazine "60 Minutes," which has been the target of <a href="https://www.benzinga.com/markets/25/02/43579254/trump-vs-cbs-president-threatens-license-over-fraud-and-claims-of-edited-kamala-harris-interview">several recent attacks</a> from the president.
"This weekend's ‘BROADCAST' tops them all. They did not one, but TWO major stories on ‘TRUMP,' one having to do with Ukraine, which I say is a War that would never have happened if the 2020 Election had not been RIGGED, in other words, if I were President and, the other story was having to do with Greenland, casting our Country, as led by me, falsely, inaccurately, and fraudulently," Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114333660655935996">said </a>in his post.
The president said he was "honored" to be suing 60 Minutes, CBS and Paramount for their "fraudulent, beyond recognition, reporting."
Trump previously <a href="https://www.benzinga.com/general/politics/24/11/41703649/trump-sues-cbs-for-10b-says-harris-interview-intended-to-mislead-the-public">sued the news magazine </a>and media company over their interview with 2024 presidential election candidate Kamala Harris.
The president said that "60 Minutes" is not a news show but a "political operative simply disguised as news."
Trump is encouraging Federal Communications Commission Chairman Brendan Carr, whom he appointed, to hold the company responsible for "what they have done."
"CBS is out of control, at levels never seen before, and they should pay a big price for this," Trump said. He added that he hopes Carr "will impose the maximum fines and punishment" for the company's alleged "unlawful and illegal behavior."
According to <a href="https://deadline.com/2025/04/trump-60-minutes-cbs-1236367575/">Deadline</a>, the weekend&#8217;s two "60 Minutes" segments were "pretty standard." One segment featured an interview with Ukrainian President Volodymyr Zelenskyy, and the other featured a journalist interviewing residents of Greenland who oppose the U.S. annexation of the country.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/02/43997957/paramount-subscriber-growth-to-slow-in-q1-2025heres-why-the-super-bowl-boost-wont-carry-over">Paramount+ Subscriber Growth To Slow In Q1 2025—Here&#8217;s Why The Super Bowl Boost Won&#8217;t Carry Over</a>
Why It's Important: Trump's latest attack on CBS and "60 Minutes" follows a $20 billion lawsuit against the company for allegedly editing the Kamala Harris interview.
The comments also come with Paramount looking to close its merger with Skydance, which faces regulatory hurdles.
While CBS denied wrongdoing, it is pursuing a mediator to settle Trump's original lawsuit, which could be a move to push the merger forward.
Trump's attack on CBS could pressure Carr and the FCC to punish the network and potentially block the merger to further punish the company. These moves come despite Trump ally Larry Ellison being set to gain majority control of the new media company if the merger goes through.
The merger deadline between Paramount and Skydance expired on April 7 and was automatically extended for 90 days. With Trump putting pressure on CBS and the FCC once again, Paramount may be forced to settle its pending lawsuit with Trump to get its merger through under its current deadline.
PARA Price Action: Paramount stock trades at $10.72 on Monday versus a 52-week trading range of $9.54 to $14.54. Paramount stock is up 1.4% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42201909/hail-to-the-victors-and-larry-ellison-billionaire-helps-michigan-football-land-top-recruit-bryce-underwood">Billionaire Larry Ellison&#8217;s Role In Landing Top Recruit Bryce Underwood At Michigan</a></li>
</ul>
Photo: Shutterstock

Entertainment

Politics

Legal

Media

PARA

PARAA

Trump Attacks '60 Minutes' For 'Unlawful And Illegal Behavior': Could President Derail Merger?

Scotiabank analyst Tanya Jakusconek maintains Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) with a Sector Outperform and raises the price target from $13 to $16.

Scotiabank Maintains Sector Outperform on Kinross Gold, Raises Price Target to $16

Raymond James analyst David Long maintains Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) with a Strong Buy and lowers the price target from $88 to $78.

Raymond James Maintains Strong Buy on Wells Fargo, Lowers Price Target to $78

WIIM

Webull shares are trading higher after the stock began trading following the completion of its SPAC merger.

HSBC analyst Liyanna Yang upgrades YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) from Reduce to Hold and raises the price target from $21 to $33.

HSBC Upgrades YPF to Hold, Raises Price Target to $33

Raymond James analyst Tim Thein maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Outperform and lowers the price target from $105 to $100.

Raymond James Maintains Outperform on Federal Signal, Lowers Price Target to $100

<a target="_blank" href="https://www.benzinga.com/quote/VERV" rel="noreferrer noopener">Verve Therapeutics Inc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">levels in the blood</a>.
VERVE-102 was well-tolerated among 14 participants across three dose levels. No treatment-related serious adverse events (SAEs) and no clinically significant laboratory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44785340/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-phase-1b-clinical-trial-of-ver" rel="noreferrer noopener">abnormalities were observed</a>.
A single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein (regulates cholesterol metabolism) levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.
VERVE-102 is a novel,&nbsp;in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the&nbsp;PCSK9&nbsp;gene in the liver and durably reduces disease-driving LDL-C.
<ul>
<li>VERVE-102 comprises an adenine base editor and a guide RNA (gRNA) targeting the&nbsp;PCSK9&nbsp;gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered as a single intravenous infusion over two to four hours.</li>
</ul>
VERVE-102 has been well-tolerated, with no treatment-related SAEs, dose-limiting toxicities, or cardiovascular events observed.
Following a single infusion of VERVE-102, dose-dependent reductions in two pharmacodynamic (PD) measures were observed: blood LDL-C and PCSK9 protein levels.
<ul>
<li>Cohort 1; 0.3 mg/kg (n=4): LDL-C reduction was 21% and PCSK9 reduction was 46%.</li>
<li>Cohort 2; 0.45 mg/kg (n=6): LDL-C reduction was 41% and PCSK9 reduction was 53%.</li>
<li>Cohort 3; 0.6 mg/kg (n=4): LDL-C reduction was 53% and PCSK9 reduction was 60%.</li>
</ul>
Across all 14 participants, VERVE-102 demonstrated a strong dose-dependent response between the amount of total RNA administered and LDL-C reductions.
The Heart-2 trial is enrolling participants in the fourth dose cohort of 0.7 mg/kg. Verve has dosed two participants in this cohort.
<ul>
<li>Verve expects to announce the final data from the dose escalation portion of the Heart-2 clinical trial, including durability data, in the second half of 2025.</li>
<li>Verve plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance.</li>
</ul>
Verve expects its current capital position to be sufficient to fund its operations into mid-2027, which includes the completion of the Phase 2 clinical trial.
Under the PCSK9 program collaboration agreement with Verve, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) holds the right to opt-in to share worldwide development expenses (33% contributed by Lilly) and to jointly commercialize and share profits and expenses related to commercialization in the U.S. on a 50/50 basis.
<ul>
<li>Verve retains control of the development and commercialization of all collaboration products in the U.S., and Verve holds all product rights outside the U.S.</li>
<li>Verve expects to deliver the opt-in package for the PCSK9 program and receive a decision from Lilly in the second half of 2025.</li>
</ul>
Last week, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VERVE-102 for hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44757920/verve-therapeutics-receives-u-s-fda-fast-track-designation-for-verve-102-an-in-vivo-base-editing-m" rel="noreferrer noopener">cholesterol (LDL-C)</a>.
Price Action: VERV stock is up 13% at $3.69 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44785962/accenture-partners-with-goupscale-to-scale-relationship-management-in-asias-digital-wealth-boom" target="_blank" rel="noreferrer noopener">Accenture Partners With GoUpscale To Scale Relationship Management In Asia&#8217;s Digital Wealth Boom</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

Movers

Trading Ideas

VERV

Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose

Raymond James analyst Simon Leopold maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Outperform and lowers the price target from $31 to $20.

AAOI

Raymond James Maintains Outperform on Applied Optoelectronics, Lowers Price Target to $20

Press Releases

Dakota Gold Corp. Announces Resource Expansion Potential with Step-Out Drill Results at Richmond Hill Gold Project

Dakota Gold Reports Further Resource Expansion at Richmond Hill with Step-Out Drilling Results

Dakota Gold Step-Out Drilling Nearly Doubles the Strike Length of Modeled Homestake Mine-Style Gold Mineralization at Maitland

Dakota Gold Intersects 2.22 grams per tonne gold over 50 meters at Richmond Hill in Drill Program to Expand Resource

Dakota Gold Announces Date for Webcast Conference Call to Review the New Resource for Richmond Hill

Dakota Gold Reports Significant Heap Leachable Gold at Richmond Hill Totaling 3.65 Million Ounces of Measured and Indicated Mineral Resources

Dakota Gold Announces Offering of Common Stock

Dakota Gold Announces Pricing of Offering of Common Stock for Gross Proceeds of Approximately $35 Million

Dakota Gold Corporate Update Following Successful Close of $35 Million Financing

Small Cap

Opinion

Gold Miners Gain Momentum as Prices Surge Back Past $3,010

LVGLF

THXPF

TSX:NGD

TSX:WGX

TSXV:LVG

TSXV:THX

WGXRF

Anglogold Ashanti

Compania De Minas

Coeur Mining

DRDGOLD Limited American Depositary Shares

DRDGold

Gold Fields Limited American Depositary Shares

Gold Fields

Gold Resource

Gold Royalty

Harmony Gold Mining Co

Hycroft Mining Holding Corporation - Class A Common Stock

Comments

Dakota Gold

Dakota Gold (DC) Opzioni

Dakota Gold (AMEX:DC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO